The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer
Open accessAbstract
// Kyung-A Hyun 1, * , Gi-Bang Koo 2, 3, * , Hyunju Han 4 , Joohyuk Sohn 5 , Wonshik Choi 6 , Seung-Il Kim 7 , Hyo-Il Jung 1 , You-Sun Kim 2, 3 1 School of Mechanical Engineering, Yonsei University, Seoul, Korea 2 Department of Biochemistry, Ajou University School of Medicine, Suwon, Korea 3 Department of Biomedical Sciences, Graduate School, Ajou University, Suwon, Korea 4 Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea 5 Department of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea 6 Department of Physics, Korea University, Seoul, Korea 7 Department of Surgery, Yonsei University College of Medicine, Seoul, Korea * These authors contributed equally to this paper Correspondence to: Seung-Il Kim, email: skim@yuhs.ac Hyo-Il Jung, email: uridle7@yonsei.ac.kr You-Sun Kim, email: yousunkim@ajou.ac.kr Keywords: epithelial cell adhesion molecule (EpCAM), EpCAM-negative, EMT-induced breast cancer cell, circulating tumor cells (CTCs), label-free separation Received: September 07, 2015 Accepted: March 04, 2016 Published: March 22, 2016 ABSTRACT The dissemination of circulating tumor cells (CTCs) requires the Epithelial-to-Mesenchymal transition (EMT), in which cells lose their epithelial characteristics and acquire more mesenchymal-like phenotypes. Current isolation of CTCs relies on affinity-based approaches reliant on the expression of Epithelial Cell Adhesion Molecule (EpCAM). Here we show EMT-induced breast cancer cells maintained in prolonged mammosphere culture conditions possess increased EMT markers and cancer stem cell markers, as well as reduced cell mass and size by quantitative phase microscopy; however, EpCAM expression is dramatically decreased in these cells. Moreover, CTCs isolated from breast cancer patients using a label-free microfluidic flow fractionation device had differing expression patterns of EpCAM, indicating that affinity approaches reliant on EpCAM expression may underestimate CTC number and potentially miss critical subpopulations. Further characterization of CTCs, including low-EpCAM populations, using this technology may improve detection techniques and cancer diagnosis, ultimately improving cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
Riethdorf, S., Fritsche, H., Müller, V., Rau, T., Schindlbeck, C., Rack, B., Janni, W., Coith, C., Beck, K., Jänicke, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1695 · Cited by 1,338
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,135
Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
Sarrió, D., Rodriguez-Pinilla, S. M., Hardisson, D., Cano, A., Moreno-Bueno, G., & Palacios, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2017 · Cited by 1,056
Gorges, T. M., Tinhofer, I., Drosch, M., Röse, L., Zollner, T. M., Krahn, T., & von Ahsen, O. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-178 · Cited by 565
Biology, detection, and clinical implications of circulating tumor cells
Joosse, S. A., Gorges, T. M., & Pantel, K. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201303698 · Cited by 528
Kim, Y.-S., Morgan, M. J., Choksi, S., & Liu, Z.-G. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.04.021 · Cited by 519
Self-citationOptical imaging of cell mass and growth dynamics
Popescu, G., Park, Y., Lue, N., Best-Popescu, C., Deflores, L., Dasari, R. R., Feld, M. S., & Badizadegan, K. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00121.2008 · Cited by 518
Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells
Grimshaw, M. J., Cooper, L., Papazisis, K., Coleman, J. A., Bohnenkamp, H. R., Chiapero-Stanke, L., Taylor-Papadimitriou, J., & Burchell, J. M. (2008) · Breast Cancer Research · doi:10.1186/bcr2106 · Cited by 339
Cited by
EMT Transition States during Tumor Progression and Metastasis
Pastushenko, I., & Blanpain, C. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.12.001 · Cited by 2,876
Bartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M., Madsen, C. D., Lindgren, D., Pekar, G., Karlsson, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07582-3 · Cited by 826
Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.011 · Cited by 598
Context-dependent EMT programs in cancer metastasis
Aiello, N. M., & Kang, Y. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181827 · Cited by 584
Tumor Heterogeneity in Breast Cancer
Turashvili, G., & Brogi, E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00227 · Cited by 561
Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis
De Rubis, G., Rajeev Krishnan, S., & Bebawy, M. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.006 · Cited by 535
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer
Wu, S. Z., Roden, D. L., Wang, C., Holliday, H., Harvey, K., Cazet, A. S., Murphy, K. J., Pereira, B., Al‐Eryani, G., Bartonicek, N., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019104063 · Cited by 436
Circulating tumour cells for early detection of clinically relevant cancer
Lawrence, R., Watters, M., Davies, C. R., Pantel, K., & Lu, Y.-J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00781-y · Cited by 370
Liquid biopsy in breast cancer: A comprehensive review
Alimirzaie, S., Bagherzadeh, M., & Akbari, M. R. (2019) · Clinical Genetics · doi:10.1111/cge.13514 · Cited by 332
Cancer stem cell in breast cancer therapeutic resistance
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.004 · Cited by 328
Boire, A., Brandsma, D., Brastianos, P. K., Le Rhun, E., Ahluwalia, M., Junck, L., Glantz, M., Groves, M. D., Lee, E. Q., Lin, N., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz012 · Cited by 183
Transcriptional regulators ensuring specific gene expression and decision-making at high TGFβ doses
Hartmann, L., Kristofori, P., Li, C., Becker, K., Hexemer, L., Bohn, S., Lenhardt, S., Weiss, S., Voss, B., Loewer, A., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202402859 · Cited by 4
Metadata
- Authors
- Hyun, K.-A., Koo, G.-B., Han, H., Sohn, J., Choi, W., Kim, S.-I., Jung, H.-I., & Kim, Y.-S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-22
- Volume
- 7
- Issue
- 17
- Pages
- 24677-24687
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2311177000
- Cited by
- 274
- References
- 23
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.